Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer

Inclusion Criteria: * Resectable t2,3,4an0-1-2m0 esophageal squamous cell carcinoma initially diagnosed by histology or cytology; * Without any systematic anti-tumor treatment; * ECOG 0-1; * ANC≥ 1.5×109/L; * PLT≥ 75×109/L; * HB≥ 8.0 g/dL; * TBIL ≤ 1.5´ ULN; * ALT and AST ≤ 2.5´ULN; * Cr ≤ 1.5´ULN or CCr ≥ 60ml/min; * Urine protein \< +, if urine protein + then the total protein in 24 hours must be \<500mg; * Blood glucose is within the normal range and / or patients with diabetes are in treatment, but blood glucose is controlled in a stable state; * FEV1 ≥ 2L; If the baseline FEV1 is less than 2L, it is estimated that the FEV1 after surgery is greater than 800ml； * No myocardial infarction within 1 year; No unstable angina pectoris; No symptomatic severe arrhythmia; No cardiac insufficiency； * There are no serious complications or other major diseases that have not been cured； * Thoracic surgeons judge those who can tolerate the operation； * Female subjects with fertility and male subjects with partners of childbearing age need to use a medically approved contraceptive measure during the study treatment and at least 6 months after the last chemotherapy； * The subjects voluntarily joined the study and signed the informed consent form Exclusion Criteria: * Received any kind of systematic anti-tumor treatment before the first use of the study drug； * At the same time, another clinical study will be included, unless it is an observational (non intervention) clinical study； * Subjects who need to be given corticosteroids (more than 10mg prednisone equivalent dose per day) or other immunosuppressants for systematic treatment within 2 weeks before the first use of the study drug； * Have been vaccinated with tumor vaccine or have been vaccinated with live vaccine within 4 weeks before administration； * Have a history of active autoimmune diseases and autoimmune diseases; Except for patients who have recovered from childhood asthma / allergy and do not need any intervention after adulthood; Autoimmune mediated hypothyroidism treated with a stable dose of thyroid hormone replacement; Use a stable dose of insulin for type I diabetes； * Serious interference occurred within 4 weeks before the first use of the study drug (CTC AE\>2); Baseline chest imaging examination showed active pulmonary inflammation, symptoms and signs of infection within 2 weeks before the first use of the study drug, or the need for oral or intravenous antibiotics； * Have a history of interstitial lung disease； * The subjects had active hepatitis B (HBV DNA ≥ 2000 IU/ml or 104copies/ml), hepatitis C (hepatitis C antibody positive and HCV-RNA higher than the lower limit of the analysis method); * Pregnant or lactating women; * There are serious complications or other major diseases that have not been cured; * Patients judged by thoracic surgeons to be intolerant of surgery